Venn and Uni­ver­si­ty of Utah part­ner on im­muno-on­col­o­gy mol­e­cule; Bio­gen los­ing an­oth­er ex­ec

→  Venn Ther­a­peu­tics plans to ad­vance a small mol­e­cule de­signed by Haitao (Mark) Ji at the Uni­ver­si­ty of Utah. The mol­e­cule is a β-catenin/BCL9 in­hibitor that they be­lieve will make tu­mors more sus­cep­ti­ble to the body’s im­mune re­sponse. β-catenin sig­nal­ing is un­der­stood to be re­spon­si­ble for can­cel cells evad­ing an­ti-tu­mor im­mu­ni­ty. Since de­vel­op­ing the mol­e­cule, Ji has moved to the Uni­ver­si­ty of South Flori­da‘s Tam­pa Bay Tech­nol­o­gy In­cu­ba­tor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.